Effect of vasoactive drugs on tumour blood flow as determined by 2h nuclear magnetic resonance spectroscopy

8Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A selective reduction in tumour blood flow (TBF) could enhance the effects of hyperthermia treatment and of drugs toxic to hypoxic cells. Vasodilator-induced changes in TBF were monitored in transplanted rat fibrosarcomas by non-invasively measuring the uptake of D2O using 2H nuclear magnetic resonance spectroscopy. Hydralazine (1 or 5 mg kg-1) caused a large (45% reduction in mean arterial blood pressure (MABP) and a 40-60% reduction in TBF. Low-dose hydralazine (0.1 mg kg-1) caused a 20% reduction in MABP but no significant change in TBF. The doses of prazosin (1 mg kg-1) and calcitonin-gene related peptide (CGRP, 1 nmol kg-1) which caused a 20% reduction in MABP led to a 50-60% reduction in TBF. These results demonstrate the advantage of prazosin and CGRP over hydralazine for the reduction of TBF despite a small hypotensive effect. CGRP may be the most suitable of these agents for clinical use because of its short physiological half-life. ©1995 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

Cite

CITATION STYLE

APA

Burney, I. A., Maxwell, R. J., Field, S. B., McCoy, C. L., & Griffiths, J. R. (1995). Effect of vasoactive drugs on tumour blood flow as determined by 2h nuclear magnetic resonance spectroscopy. Acta Oncologica, 34(3), 367–371. https://doi.org/10.3109/02841869509093991

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free